QbD Model Case Study of MONOCLONAL ANTIBODY : A-Mab.Shivang Chaudhary
The A-Mab Case Study involved the efforts of many individuals from CMC-BWG and would not have been made possible if it were not for the countless number of hours spent by the 5 participating companies (GlaxosmithKline, MedImmune, Merck, Pfizer, PWC and sanofi pasteur).
This presentation is compiled by “ Drug Regulations” from freely available resources like the FDA on the World wide web. “Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals.
This document discusses guidelines for assessing elemental impurities in pharmaceutical products according to ICH Q3D. It describes a risk-based approach to evaluating potential sources of elemental impurities from drug substances, excipients, equipment and processing aids. Specific approaches are provided for assessing impurities from metal catalysts, water sources, and packaging materials. The presentation emphasizes controlling impurities through an understanding of manufacturing processes and applying appropriate testing and control strategies.
Role of quality by design (qb d) in quality assurance of pharmaceutical productNitin Patel
This document discusses the role of Quality by Design (QbD) in assuring quality of pharmaceutical products. It defines QbD and compares the traditional quality assessment system to the QbD approach. The document outlines the steps of a QbD program, including defining target quality profiles, identifying critical quality attributes and process parameters, designing the manufacturing process and establishing a control strategy. It also discusses tools used in QbD like design of experiments and risk assessment.
Understanding How Bioburden and Sterilization Affect Medical DevicesPacific BioLabs
1) Bioburden refers to microorganisms present on medical devices and must be monitored and controlled as high levels can compromise sterilization validation.
2) Sterilization methods like gamma, e-beam, and ethylene oxide are effective when bioburden levels are properly determined and accounted for in the sterilization dose.
3) Maintaining low and consistent bioburden through environmental monitoring, personnel training, cleaning processes, and device design is essential for ensuring sterilized medical devices.
The document discusses ICH Q3D guidelines for controlling elemental impurities in pharmaceutical products. It defines elemental impurities as metals that have no therapeutic benefit and should be limited. The guidelines establish permitted daily exposures for 24 elements of concern and provide a risk-based approach to control impurities. Elements are classified based on their toxicity into Classes 1-3. The risk assessment process identifies potential sources of impurities and evaluates predicted levels. Control methods include modifying manufacturing processes, establishing specifications limits for materials and products, and selecting appropriate container systems. The guidelines provide options to convert permitted daily exposures into concentration limits for individual components and finished products.
Best techniques to control Genotoxities and impact of ICH M7 guidelineBhaswat Chakraborty
This document discusses best techniques to control genotoxic impurities according to the ICH M7 guideline. It covers the scope and principles of ICH M7, including risk assessment of potential genotoxic impurities in drug substances and products. It also discusses classification of impurities, acceptable intake levels, control options, and retrospective application of ICH M7 to marketed products. The goal is to limit risk from genotoxic impurities to virtually safe levels through appropriate testing, control, and documentation strategies.
Quality by Design Principles Applied to Sterilizing Filtration by Michael PayneMerck Life Sciences
Key regulatory documents and regulatory thinking now includes quality by design (QbD). This webinar focuses on how to integrate practical QbD activities into the process and analytical aspects of sterile medicinal product sterilizing filtration and qualification.
In this webinar, you will learn to:
• Focus on practical QbD terms and approaches
• Highlight critical product quality aspects of sterile medicinal products
• Develop design and control spaces for sterilizing filtration
• Easily integrate QbD into the process and analytical operations in early phase development and into manufacturing phase production
Abstract:
Final sterilizing filtration is the last operation in downstream processing to assure the sterility of medicinal products. Poorly defined product attributes process parameters may attract regulatory scrutiny, affect final product sterility and patient safety. A better understanding of QbD concepts and principles allows for better process and analytical monitoring and control at both early and final phase production. The webinar will show how currently available process cGMP information can be practically incorporated into QbD product quality attributes and process parameters. This is especially vital for the third party conducted laboratory work such as bacterial retention and leachable studies.
QbD Model Case Study of MONOCLONAL ANTIBODY : A-Mab.Shivang Chaudhary
The A-Mab Case Study involved the efforts of many individuals from CMC-BWG and would not have been made possible if it were not for the countless number of hours spent by the 5 participating companies (GlaxosmithKline, MedImmune, Merck, Pfizer, PWC and sanofi pasteur).
This presentation is compiled by “ Drug Regulations” from freely available resources like the FDA on the World wide web. “Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals.
This document discusses guidelines for assessing elemental impurities in pharmaceutical products according to ICH Q3D. It describes a risk-based approach to evaluating potential sources of elemental impurities from drug substances, excipients, equipment and processing aids. Specific approaches are provided for assessing impurities from metal catalysts, water sources, and packaging materials. The presentation emphasizes controlling impurities through an understanding of manufacturing processes and applying appropriate testing and control strategies.
Role of quality by design (qb d) in quality assurance of pharmaceutical productNitin Patel
This document discusses the role of Quality by Design (QbD) in assuring quality of pharmaceutical products. It defines QbD and compares the traditional quality assessment system to the QbD approach. The document outlines the steps of a QbD program, including defining target quality profiles, identifying critical quality attributes and process parameters, designing the manufacturing process and establishing a control strategy. It also discusses tools used in QbD like design of experiments and risk assessment.
Understanding How Bioburden and Sterilization Affect Medical DevicesPacific BioLabs
1) Bioburden refers to microorganisms present on medical devices and must be monitored and controlled as high levels can compromise sterilization validation.
2) Sterilization methods like gamma, e-beam, and ethylene oxide are effective when bioburden levels are properly determined and accounted for in the sterilization dose.
3) Maintaining low and consistent bioburden through environmental monitoring, personnel training, cleaning processes, and device design is essential for ensuring sterilized medical devices.
The document discusses ICH Q3D guidelines for controlling elemental impurities in pharmaceutical products. It defines elemental impurities as metals that have no therapeutic benefit and should be limited. The guidelines establish permitted daily exposures for 24 elements of concern and provide a risk-based approach to control impurities. Elements are classified based on their toxicity into Classes 1-3. The risk assessment process identifies potential sources of impurities and evaluates predicted levels. Control methods include modifying manufacturing processes, establishing specifications limits for materials and products, and selecting appropriate container systems. The guidelines provide options to convert permitted daily exposures into concentration limits for individual components and finished products.
Best techniques to control Genotoxities and impact of ICH M7 guidelineBhaswat Chakraborty
This document discusses best techniques to control genotoxic impurities according to the ICH M7 guideline. It covers the scope and principles of ICH M7, including risk assessment of potential genotoxic impurities in drug substances and products. It also discusses classification of impurities, acceptable intake levels, control options, and retrospective application of ICH M7 to marketed products. The goal is to limit risk from genotoxic impurities to virtually safe levels through appropriate testing, control, and documentation strategies.
Quality by Design Principles Applied to Sterilizing Filtration by Michael PayneMerck Life Sciences
Key regulatory documents and regulatory thinking now includes quality by design (QbD). This webinar focuses on how to integrate practical QbD activities into the process and analytical aspects of sterile medicinal product sterilizing filtration and qualification.
In this webinar, you will learn to:
• Focus on practical QbD terms and approaches
• Highlight critical product quality aspects of sterile medicinal products
• Develop design and control spaces for sterilizing filtration
• Easily integrate QbD into the process and analytical operations in early phase development and into manufacturing phase production
Abstract:
Final sterilizing filtration is the last operation in downstream processing to assure the sterility of medicinal products. Poorly defined product attributes process parameters may attract regulatory scrutiny, affect final product sterility and patient safety. A better understanding of QbD concepts and principles allows for better process and analytical monitoring and control at both early and final phase production. The webinar will show how currently available process cGMP information can be practically incorporated into QbD product quality attributes and process parameters. This is especially vital for the third party conducted laboratory work such as bacterial retention and leachable studies.
This document outlines stability testing recommendations for different drug formulations, including whether acid-base, oxidative, photo-stability, thermal, or thermal-humidity testing is necessary or optional. It also describes how forced degradation studies are used to evaluate drug substance and product stability in various conditions, identify possible degradation pathways and products, and facilitate improvements to manufacturing and formulations.
The document discusses analytical target profiles (ATPs), which describe the required quality of results from analytical procedures. ATPs connect all stages of a procedure's lifecycle by stating acceptable error in measurements. They establish predefined performance requirements. Two example ATPs are provided. ATP #1 specifies accuracy and precision criteria for reportable values. ATP #2 specifies a target measurement uncertainty of ±C%. Advantages and limitations of each approach are discussed. The document emphasizes that ATPs should consider measurement uncertainty and the risk of making incorrect decisions based on results.
The document discusses nitrosamine impurities, which are carcinogenic compounds that have been found in some generic drug substances and products. It notes that regulatory agencies announced the presence of specific nitrosamines like NDMA and NDEA in drugs like ARBs, pioglitazone, and ranitidine. The document then provides background on nitrosamines and how they can be generated during drug manufacturing through use of reagents, catalysts, solvents or raw materials containing amines or nitrites. It outlines sources of nitrosamine impurities and recommends ways to prevent their formation, such as avoiding use of amines with nitrosating agents, properly storing materials, cleaning equipment, and modifying processes.
The document provides guidelines for specifications of new drug substances and products. It discusses setting specifications based on development data and stability studies. Universal tests for drug substances include identification, assay, impurities. For products, additional tests depend on dosage form and may include dissolution, uniformity, sterility. The guidelines provide concepts for justifying specifications and periodic testing. They apply principles for biotech products, addressing characterization, analytical validation, process controls, and linking specifications to manufacturing and clinical data.
EU and US Procedures for API Registration - Commonalities and DifferencesMerck Life Sciences
View the interactive recording here: https://bit.ly/2PB0VZo
Abstract:
This webinar will review the current requirements for the active substance registration in the European Union and the USA. First, we will summarize the authority regulations for APIs in the EU and USA and show the similarities and differences of procedures such as CEP, AMSF, and US-DMF. Secondly, we’ll cover new trends and requirements for API-dossiers such as the control of elemental impurities according to the new international guideline ICH Q3D and related watchouts for CEPs. At the end of the presentation, we’ll discuss the eCTD roadmap for the future and the end of paper submissions.
This document provides information about nitrosamine impurities found in angiotensin II receptor blockers (ARBs) like valsartan, losartan, and irbesartan. It discusses how various nitrosamine impurities like NDMA, NDEA, and NMBA were discovered in 2018-2019 through recalls of ARB medications from multiple manufacturers. It outlines the global investigations and testing methods developed by regulatory agencies like the FDA to detect these genotoxic and carcinogenic impurities and ensure the safety of the drug supply.
To compare filing process of NDA of different countries of India, US and Euro...Aakashdeep Raval
To compare filing process of NDA of different countries of India, US and Europe.
B) Preparation of global list documents of registration of IND and NDA as per USFDA and Europe.
This document discusses ICH guidelines related to impurities in new drug substances and products. It defines key terms like impurity, identified impurity, and potential impurity. It categorizes impurities as organic, inorganic, or residual solvents. The guidelines provide thresholds for identification, qualification, and reporting of impurities. They also classify residual solvents and elemental impurities based on their toxicity, providing permissible daily exposure limits. The guidelines aim to establish qualification of impurities at levels present in early clinical trials and provide a risk-based approach to control impurities.
Impurities ICH Q3 Guidelines Au Vivek JainVivek Jain
This document provides an overview of ICH Q3 guidelines for impurities in pharmaceutical products. It defines impurities and discusses the objectives of controlling impurities. It describes different types of impurities including organic, inorganic, and residual solvents. It outlines ICH Q3A-Q3D guidelines and definitions related to impurities and degradation products. It also discusses thresholds for identifying, reporting, and qualifying degradation products in new drug products.
ICH Q3D - Elemental impurities in pharmaceutical productspi
The ICH has developed the Q3D guideline on elemental impurities. Both the FDA and the EMA encourage the ICH Q3D guideline implementation. All companies will have to be compliant for already authorised and marketed products as of December 2017.
This document discusses Process Analytical Technology (PAT). It begins with an introduction to PAT, defining it as a system to design, analyze, and control manufacturing through timely measurements of critical quality attributes. It then discusses how PAT works by selecting a suitable PAT system and identifying critical process parameters. It highlights some key benefits of PAT such as improving process understanding and control, enhancing safety, and reducing variation. The document also provides examples of common PAT applications and discusses regulatory guidance around implementing PAT from agencies like the FDA.
In this webinar, you will learn:
Trends in vaccine manufacturing
Innovative solutions in facility design
Case studies and proposals for future vaccine factories
Considerations while setting up Quality Management Systems (QMSs)
How validation helps accelerate regulatory approval
Detailed description:
How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities?
The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.
1) This document discusses Statistical Process Control (SPC), which uses statistical methods to monitor and control processes to ensure they operate at full potential. SPC aims to maximize conforming product output while minimizing waste.
2) Key aspects of SPC include understanding variation in processes, distinguishing between common and special causes of variation, using statistical tools like control charts to monitor processes and detect issues, and taking action to control processes and continually improve quality.
3) The document outlines the basic elements of a process control system, including gathering performance information, taking action on processes and outputs, and using feedback to maintain stability and reduce variation. It emphasizes prevention over detection to avoid waste.
2.6.12. microbiological examination of non sterile products (total viable aer...Guide_Consulting
This document provides instructions for performing a total viable aerobic count test to quantify bacteria and fungi that may be present in non-sterile pharmaceutical products. The test involves preparing samples from the product, then examining the samples using membrane filtration or plate counting methods to determine the number of colony forming units per gram or milliliter of product. Specific steps are outlined for preparing water-soluble products, non-fatty insoluble products, fatty products, and transdermal patches. The document also provides details on conducting membrane filtration, pour plate, surface spread, and most probable number examination methods and calculating results.
Analysis of elemental impurities in APIDr. Amsavel A
The document discusses guidelines for controlling elemental impurities in active pharmaceutical ingredients (APIs) according to new regulatory requirements. It provides an overview of:
1) Background guidelines from various regulatory agencies on limiting elemental impurities.
2) Reasons for the new requirements to replace heavy metal testing, including difficulties with reproducibility and safety of current methods.
3) Classification of elemental impurities based on toxicity and permissible intake limits set by the ICH.
It also outlines procedures for method development, validation, and implementation of elemental impurity testing and control as defined in USP general chapters 232 and 233.
Discussed about commercial product post-approval variation management as per ICH guideline Q12 Product LifeCycle Management. Covers the Risk-based Variation Categorisation and making effective communication between MAH and Authority.
This Annex describes the principles of qualification and validation which are applicable to the facilities, equipment, utilities and processes used for the manufacture of medicinal products and may also be used as supplementary optional guidance for active substances without introduction of additional requirements to EudraLex, Volume 4, Part II. It is a GMP requirement that manufacturers control the critical aspects of their particular operations through qualification and validation over the life cycle of the product and process. Any planned changes to the facilities, equipment, utilities and processes, which may affect the quality of the product, should be formally documented and the impact on the validated status or control strategy assessed. Computerised systems used for the manufacture of medicinal products should also be validated according to the requirements of Annex 11. The relevant concepts and guidance presented in ICH Q8, Q9, Q10 and Q11 should also be taken into account.
Highlights of the guidance are given in following presentation.
This document outlines stability testing recommendations for different drug formulations, including whether acid-base, oxidative, photo-stability, thermal, or thermal-humidity testing is necessary or optional. It also describes how forced degradation studies are used to evaluate drug substance and product stability in various conditions, identify possible degradation pathways and products, and facilitate improvements to manufacturing and formulations.
The document discusses analytical target profiles (ATPs), which describe the required quality of results from analytical procedures. ATPs connect all stages of a procedure's lifecycle by stating acceptable error in measurements. They establish predefined performance requirements. Two example ATPs are provided. ATP #1 specifies accuracy and precision criteria for reportable values. ATP #2 specifies a target measurement uncertainty of ±C%. Advantages and limitations of each approach are discussed. The document emphasizes that ATPs should consider measurement uncertainty and the risk of making incorrect decisions based on results.
The document discusses nitrosamine impurities, which are carcinogenic compounds that have been found in some generic drug substances and products. It notes that regulatory agencies announced the presence of specific nitrosamines like NDMA and NDEA in drugs like ARBs, pioglitazone, and ranitidine. The document then provides background on nitrosamines and how they can be generated during drug manufacturing through use of reagents, catalysts, solvents or raw materials containing amines or nitrites. It outlines sources of nitrosamine impurities and recommends ways to prevent their formation, such as avoiding use of amines with nitrosating agents, properly storing materials, cleaning equipment, and modifying processes.
The document provides guidelines for specifications of new drug substances and products. It discusses setting specifications based on development data and stability studies. Universal tests for drug substances include identification, assay, impurities. For products, additional tests depend on dosage form and may include dissolution, uniformity, sterility. The guidelines provide concepts for justifying specifications and periodic testing. They apply principles for biotech products, addressing characterization, analytical validation, process controls, and linking specifications to manufacturing and clinical data.
EU and US Procedures for API Registration - Commonalities and DifferencesMerck Life Sciences
View the interactive recording here: https://bit.ly/2PB0VZo
Abstract:
This webinar will review the current requirements for the active substance registration in the European Union and the USA. First, we will summarize the authority regulations for APIs in the EU and USA and show the similarities and differences of procedures such as CEP, AMSF, and US-DMF. Secondly, we’ll cover new trends and requirements for API-dossiers such as the control of elemental impurities according to the new international guideline ICH Q3D and related watchouts for CEPs. At the end of the presentation, we’ll discuss the eCTD roadmap for the future and the end of paper submissions.
This document provides information about nitrosamine impurities found in angiotensin II receptor blockers (ARBs) like valsartan, losartan, and irbesartan. It discusses how various nitrosamine impurities like NDMA, NDEA, and NMBA were discovered in 2018-2019 through recalls of ARB medications from multiple manufacturers. It outlines the global investigations and testing methods developed by regulatory agencies like the FDA to detect these genotoxic and carcinogenic impurities and ensure the safety of the drug supply.
To compare filing process of NDA of different countries of India, US and Euro...Aakashdeep Raval
To compare filing process of NDA of different countries of India, US and Europe.
B) Preparation of global list documents of registration of IND and NDA as per USFDA and Europe.
This document discusses ICH guidelines related to impurities in new drug substances and products. It defines key terms like impurity, identified impurity, and potential impurity. It categorizes impurities as organic, inorganic, or residual solvents. The guidelines provide thresholds for identification, qualification, and reporting of impurities. They also classify residual solvents and elemental impurities based on their toxicity, providing permissible daily exposure limits. The guidelines aim to establish qualification of impurities at levels present in early clinical trials and provide a risk-based approach to control impurities.
Impurities ICH Q3 Guidelines Au Vivek JainVivek Jain
This document provides an overview of ICH Q3 guidelines for impurities in pharmaceutical products. It defines impurities and discusses the objectives of controlling impurities. It describes different types of impurities including organic, inorganic, and residual solvents. It outlines ICH Q3A-Q3D guidelines and definitions related to impurities and degradation products. It also discusses thresholds for identifying, reporting, and qualifying degradation products in new drug products.
ICH Q3D - Elemental impurities in pharmaceutical productspi
The ICH has developed the Q3D guideline on elemental impurities. Both the FDA and the EMA encourage the ICH Q3D guideline implementation. All companies will have to be compliant for already authorised and marketed products as of December 2017.
This document discusses Process Analytical Technology (PAT). It begins with an introduction to PAT, defining it as a system to design, analyze, and control manufacturing through timely measurements of critical quality attributes. It then discusses how PAT works by selecting a suitable PAT system and identifying critical process parameters. It highlights some key benefits of PAT such as improving process understanding and control, enhancing safety, and reducing variation. The document also provides examples of common PAT applications and discusses regulatory guidance around implementing PAT from agencies like the FDA.
In this webinar, you will learn:
Trends in vaccine manufacturing
Innovative solutions in facility design
Case studies and proposals for future vaccine factories
Considerations while setting up Quality Management Systems (QMSs)
How validation helps accelerate regulatory approval
Detailed description:
How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities?
The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.
1) This document discusses Statistical Process Control (SPC), which uses statistical methods to monitor and control processes to ensure they operate at full potential. SPC aims to maximize conforming product output while minimizing waste.
2) Key aspects of SPC include understanding variation in processes, distinguishing between common and special causes of variation, using statistical tools like control charts to monitor processes and detect issues, and taking action to control processes and continually improve quality.
3) The document outlines the basic elements of a process control system, including gathering performance information, taking action on processes and outputs, and using feedback to maintain stability and reduce variation. It emphasizes prevention over detection to avoid waste.
2.6.12. microbiological examination of non sterile products (total viable aer...Guide_Consulting
This document provides instructions for performing a total viable aerobic count test to quantify bacteria and fungi that may be present in non-sterile pharmaceutical products. The test involves preparing samples from the product, then examining the samples using membrane filtration or plate counting methods to determine the number of colony forming units per gram or milliliter of product. Specific steps are outlined for preparing water-soluble products, non-fatty insoluble products, fatty products, and transdermal patches. The document also provides details on conducting membrane filtration, pour plate, surface spread, and most probable number examination methods and calculating results.
Analysis of elemental impurities in APIDr. Amsavel A
The document discusses guidelines for controlling elemental impurities in active pharmaceutical ingredients (APIs) according to new regulatory requirements. It provides an overview of:
1) Background guidelines from various regulatory agencies on limiting elemental impurities.
2) Reasons for the new requirements to replace heavy metal testing, including difficulties with reproducibility and safety of current methods.
3) Classification of elemental impurities based on toxicity and permissible intake limits set by the ICH.
It also outlines procedures for method development, validation, and implementation of elemental impurity testing and control as defined in USP general chapters 232 and 233.
Discussed about commercial product post-approval variation management as per ICH guideline Q12 Product LifeCycle Management. Covers the Risk-based Variation Categorisation and making effective communication between MAH and Authority.
This Annex describes the principles of qualification and validation which are applicable to the facilities, equipment, utilities and processes used for the manufacture of medicinal products and may also be used as supplementary optional guidance for active substances without introduction of additional requirements to EudraLex, Volume 4, Part II. It is a GMP requirement that manufacturers control the critical aspects of their particular operations through qualification and validation over the life cycle of the product and process. Any planned changes to the facilities, equipment, utilities and processes, which may affect the quality of the product, should be formally documented and the impact on the validated status or control strategy assessed. Computerised systems used for the manufacture of medicinal products should also be validated according to the requirements of Annex 11. The relevant concepts and guidance presented in ICH Q8, Q9, Q10 and Q11 should also be taken into account.
Highlights of the guidance are given in following presentation.
즐거운 마음, 다양한 주제, 뛰어난
영감<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
투이컨설팅 이그나이트(Ignite) Y세미나(14)
Ignite Y세미나 내용
1. 제조업에서 IT의
역할 : 강성구 한글라스 상무
2. 세상에서 가장 많이 팔린 명작동화 이야기 : 김규동 JDF 대표
3. 청년인재 직업 선택의 편향에 대하여 : 김대호 사회디자인연구소 소장
4. When you face a problem : 김용훈 투이컨설팅
수석
5. MMORPG와 인생, 목표설정이
중요하다 : 김은정 투이컨설팅 컨설턴트
6. 컨설팅은 무엇일까 : 김인현
투이컨설팅 대표
7. 프로그래밍 몰라도 앱 개발 즐기는 DIY 기법 : 김창수 데브멘토 팀장
8. 6시그마를 적용한 IT 서비스
개선 : 김희선 동부CNI 과장
9. 편리한 소셜 쇼핑을 위한
must have item : 문희진 투이컨설팅 책임
10. 제안서 문화, 이제
좀 바꿔봅시다 : 배정연 투이컨설팅 선임
11. 기자와 컨설턴트, 공통점과
차이점 : 성현희 전자신문 기자
12. 성공적인 New
Business Model 개발하기 : 손준호 투이컨설팅 선임
13. 살아있는 EA 만들기 : 신신애 한국정보화진흥원 박사
14. 2015년 투이의 약속 : 임동진
투이컨설팅 상무
15. 참을 수 없는 본능 – 시선 : 임창빈 투이컨설팅 선임
16. 좌씨의 즐거운 SW 품질관리의
하루 : 좌민수 제네시스기술 상무
17. 엉터리 문장의 습관 : 주동식
투이컨설팅 전문위원
18 소프트웨어 라이프사이클 관리(SLM)
적용방안 : 편흥렬 삼정KPMG 이사
AgitarOne은 Java로 개발중인 Eclipse 프로젝트에 자동화된 단위 테스트의 환경을 제공하여 테스트 시간을 대폭 단축 시켜 개발 비용을 절감하게 하며, 작성된 소스 코드들이 실질적으로 수행되는지 명확히 파악할 수 있도록 하여 소스 코드의 품질을 향상시켜 줄 수 있는 Java 개발자의 단위 테스트 자동화 솔루션 입니다.
스마트 제조는 모든 제조업의 생존 전략에 선택이 아니 필수로 인식되고 있다. MES는 생산 현장의 시시각각 변화는 생산 자원(4M1E: Man, Machine, Material, Method, Energy)을 실시간 통합과 생산정보화를 통하여 스마트제조의 기반인 공장 운영 최적화를 제공합니다.
본 강의는 스마트 제조에서 MES의 위치와 역할과 이에 필수적으로 요구되는 국제 표준화 내용 및 참조 모델, 국내외 제조 중소기업에서 산업별 적용 시 실패 및 성공 사례를 소개하고, 스마트 제조에서 MES 구축 시 필수적으로 고려할 사항에 대해 설명한다.
NPV | Life sciences valuation using Decision Tree, Monte Carlo and sensitivit...Sung-Joo LEE
주제5) 생명과학 기술가치평가와 R&D 포트폴리오 관리
생명과학 분야인 바이오 및 제약 사업에서 개발되는 신약, 각종 건강 식품 등은 제품 개발기간과 비용 회수 기간이 길고, 또 시장에 출시 되었을 때의 risk가 커서 전통적으로 가치평가를 한다는 것이 매우 어려운 분야이다. 이러한 이유로 이미 미국을 비롯한 선진 국가들과 세계 글로벌 기업에서 신제품에 대한 리스크를 보다 정확하게 측정하고 관리하기 위하여 시뮬레이션을 활용한 확률론적 방법론을 이용하고 있다. 이에 본 발표는 시뮬레이션 기법들 중에서 가장 일반적이고 우수한 Monte carlo simulation을 이용하였으며, sensitivity 분석 및 최적화를 통해서 주요 영향 요인 및 최적화 알고리즘을 통한 포트폴리오 관리법에 대해서 소개하고자 한다.
Similar to 1-1: 바이오 의약품 공정 개발 및 특성 분석을 위한 DOE 연구 사례 (20)
The document discusses improving engineering efficiency through the use of analytics. It describes how JMP software helps individuals, teams, and organizations increase engineering efficiency by enabling faster problem solving, proactive process improvement, and more productive use of time. Examples are given of companies that saw improvements such as reducing design time by over 75% and reducing data preparation work from one week to 15 minutes through the use of JMP analytics.
실험 설계의 강화 - 단순함에서 정교함으로 (Empowering Experimental Designs: From Simplicity to Sophistication)
Ryan Lekivetz (JMP), Elizabeth Claassen (JMP)
Discovery Summit Korea 2023
The document discusses JMP and Python for statistical analysis and data science. It provides a SWOT analysis comparing the strengths, weaknesses, opportunities, and threats of each. While JMP has strengths in its user-friendly GUI and built-in statistical tools, Python has advantages in its open source nature, scalability, and versatility. The document argues that both JMP and Python are needed - JMP for common statistical analyses and visualization, and Python for tasks like data preprocessing, machine learning, and automation. It proposes training to help users integrate the two platforms.
Hi-JMP is a platform developed by SK hynix to improve data analysis efficiency and enable sharing of analysis content. It provides an app store, development console, and home interface to allow users to search, deploy, customize, and run JMP applications without installation. The platform uses dynamic UI, no-installation deployment, and a backend API to integrate various data sources and automate repetitive analysis tasks. A demo showed the app store, development console, and home features in action.
The document discusses using negative space in figure drawing to help draw the figure more easily. It then discusses using negative design space exploration in early stage naval ship design rather than positive design. This allows removing constraints to identify uncertainties and define feasible design ranges earlier to support decision making. Dynamic visualization tools are proposed to allow quicker exploration of design space, generation of more design alternatives, and obtaining insights from sensitivity analysis earlier in the design process.
3. QbD 기반 의약품 개발 workflow
공정특성분석
Process Characterization
의약품 품질목표 (QTPP: Quality Target Product Profile) 설정
중요품질속성
(CQA, Critical Quality Attributes)
(Y)
중요공정변수
(CPP, Critical Process Parameter)
(X)
공정과 품질과의 상관관계
수학적 model 로 정립
Quality by Design
(QbD)
설계기반 품질고도화
안정적 품질 관리 전략
통계적 접근
Dahmash EZ, Al-khattawi A, Iyire A, Al-Yami H, Dennison TJ, Mohammed AR (2018) Quality by Design (QbD)
based process optimisation to develop functionalised particles with modified release properties using novel dry
particle coating technique. PLoS ONE 13(11): e0206651. https://doi.org/10.1371/journal.pone.0206651
의약품 개발에 있어 합리적인
과학과 품질리스크 관리를
기반으로,
목표를 미리 정하고,
제품과 공정의 이해,
그리고 공정 관리를
중요시하는 체계적인 개발 방식
(ICH Q8(R2) 가이드라인)
3 / 22
4. [Case] Process Characterization
[사례 문헌] Applying the Quality by Design to Robust Optimization and Design Space Define for Erythropoietin Cell Culture Process
단백질 의약품 배양 공정의
process characterization 을
위해 DoE 연구 수행
관리 전략 (NOR, Normal
Operating Range) 도출
Simulation 을 통한 관리
전략의 강건성 (robustness)
확인
4 / 22
5. Step for Process Characterization
▪ Step 1. DoE Design
▪ Step 2. 결과 확인 / 이상치 (Outlier)의 추정 & 확인
▪ Step 3. Model 최적화 및 확인
▪ Step 4. 중요공정변수 (CPP) 확정
▪ Step 5. 관리 전략 수립
5 / 22
6. Step 1. DoE Design
Critical Quality Attributes
Potential Critical Process Parameter
D-optimal Design, total run : 18 run
Model : main, interaction, quadratic (≒RSM)
6 / 22
7. Step 2. 결과 확인 / 이상치 (Outlier)의 추정 & 확인
Distribution & Multivariate analysis,
Explore Outliers, etc.... Fit model
Outlier
Not Outlier
7 / 22
10. Step 3. Model 최적화 및 확인
General Criteria for Model : P-value of Model ≤ 0.05, R2 adjust ≥ 0.7
경우에 따라서는 별도의 기준 정립 (예, Predicted R2, Lack of fit, VIF……)
10 / 22
11. Step 4. 중요공정변수 (CPP) 확정
어떤 공정변수 (factor) 가 품질 (response)에 중요 (critical)한 인자인가?
→ Critical 에 대한 기준 필요
HCP
11 / 22
12. Step 4. 중요공정변수 (CPP) 확정
Impact Ratio (Roche)
◆ An Improved Impact Ratio for Identifying Critical Process Parameters in Pharmaceutical Manufacturing Processes, PDA Journal of Pharmaceutical Science and
Technology November 2022, 76 (6) 497-508; DOI: https://doi.org/10.5731/pdajpst.2021.012662
◆ NCS conference 2022 : https://ncs-conference.org/wp-content/uploads/2022/12/Lamerz-D3-20m-V2-An-update-on-Roche_s-experience-with-the-Impact-Ratio-year-
six.pdf
N = the distance between the predicted CQA at the
process parameter’s high setting and the
average CQA at the process parameter’s target
setting.
D = the distance between the upper CQA acceptance
limit and the average CQA at the
process parameter’s target setting
𝑰𝒎𝒑𝒂𝒄𝒕 𝑹𝒂𝒕𝒊𝒐(%) =
𝑵
𝑫
× 𝟏𝟎𝟎
Critical? Impact ratio ≥ 30%
12 / 22
13. Step 4. 중요공정변수 (CPP) 확정
% of Tolerance, Margin, Mean (TLC) (example) Response = Estimate x Factor + intercept
Estimate = 1
Full effect = 2
Tolerance =
USL-LSL = 2
% of Tolerance =
① Response 의 기준이 있으며, 양측 기준일 경우 : % 𝑜𝑓 𝑇𝑜𝑙𝑒𝑟𝑎𝑛𝑐𝑒 = |
𝐹𝑢𝑙𝑙 𝑒𝑓𝑓𝑒𝑐𝑡
(𝑈𝑆𝐿 −𝐿𝑆𝐿)
| × 100
② Response 의 기준이 있으며, 단측 기준일 경우 : % 𝑜𝑓 𝑀𝑎𝑟𝑔𝑖𝑛 = |
𝐹𝑢𝑙𝑙 𝑒𝑓𝑓𝑒𝑐𝑡
(𝑆𝑝𝑒𝑐 𝐿𝑖𝑚𝑖𝑡−𝐴𝑣𝑒𝑟𝑎𝑔𝑒)
| × 100
③ Response 의 기준이 없을 경우 : % 𝑜𝑓 𝑀𝑒𝑎𝑛 = |
𝐹𝑢𝑙𝑙 𝑒𝑓𝑓𝑒𝑐𝑡
𝐴𝑣𝑒𝑟𝑎𝑔𝑒
| × 100
Full effect의 계산
① Main & interaction effect (1차 방정식) 일 경우 : Scaled Estimate × 2
② quadratic effect (2차 방정식) 일 경우 : Scaled Estimate × 1
Estimate = 0.2
Full effect = 1
Estimate = 0.1
Full effect = 0.2
Estimate = 0
Full effect = 0
% of Tol. = 100% % of Tol. = 50% % of Tol. = 10% % of Tol. = 0%
Critical? ≥20%
Identifying and Controlling CPPs and CMAs, Published on: March 1, 2018, Thomas A. Little, BioPharm International,
BioPharm International-03-01-2018, Volume 31, Issue 3, Pages: 38-43 13 / 22
14. Step 4. 중요공정변수 (CPP) 확정
Critical Process Parameter??
Spec. of HCP : ≤300,000
14 / 22
15. Step 5 : 관리 전략 수립 (최적 조건 or 최적 운용 범위 도출)
Spec. of HCP : ≤300,000
Contour Profiler
Contour Profiler 을 통해 가정 안정한 운용 지점 탐색
15 / 22
16. Spec. of HCP : ≤300,000
Contour Profiler
Step 5 : 관리 전략 수립 (최적 조건 or 최적 운용 범위 도출)
Monte Carlo Simulation
Design Space Profiler
강건한 운용범위 탐색
Monte Carlo
simulation 을 통해
강건한 운용범위 입증
16 / 22
17. 이제 통계tool을 사용해서
DoE도 설계하고, 실험도 하고, 적절한 모델도 도출하고,
중요인자도 확인하고, 공정관리전략까지
쉽게 할 수 있겠죠?
통계는 커녕 software 사용법도 이해도 어렵고
내가 전공도 아닌데, 복잡하고 여전히 어려운데?
내가 한 걸 믿을 순 있을까? 실수하지 않을까?
복잡한 건 클릭 한번 하면
한번에 결과 나올 수 없을까?
절차에 대해 가이드 마련
필요한 기준 설정
복잡한 절차 자동화
17 / 22
18. Step for Process Characterization
▪ Pre-Step. General Preference
▪ 동일한 Preference 로 설정
▪ Step 1. DoE Design
▪ Custom Design, Classic DoE, Easy DoE ..
▪ Step 2. 결과 확인 / 이상치 (Outlier)의 추정 & 확인
▪ Distribution & Multivariate analysis, Explore Outliers → Fit model
▪ Step 3. Model 최적화 및 확인
▪ Fit model report → model 평가
▪ Step 4. 중요공정변수 (CPP) 확정
▪ Fit model report 결과 → CPP 평가
▪ Step 5. 관리 전략 수립
▪ Profiler (Contour & Design Space Profiler, simulation)
자동화 (JMP script & add-in)
평가 기준 설정
자동화 (JMP script & add-in)
평가 기준 설정
자동화 (JMP script & add-in)
18 / 22
21. Model Evaluation & CPP identification Tool
Model Evaluation
CPP identification
Rule
21 / 22
22. Step for Process Characterization
▪ Pre-Step. General Preference
▪ 동일한 Preference 로 설정
▪ Step 1. DoE Design
▪ Custom Design, Classic DoE, Easy DoE ..
▪ Step 2. 결과 확인 / 이상치 (Outlier)의 추정 & 확인
▪ Distribution & Multivariate analysis, Explore Outliers → Fit model
▪ Step 3. Model 최적화 및 확인
▪ Fit model report → model 평가
▪ Step 4. 중요공정변수 (CPP) 확정
▪ Fit model report 결과 → CPP 평가
▪ Step 5. 관리 전략 수립
▪ Profiler (Contour & Design Space Profiler, simulation)
자동화 (JMP script & add-in)
평가 기준 설정
자동화 (JMP script & add-in)
평가 기준 설정
자동화 (JMP script & add-in)
22 / 22